The Melanoma Research Alliance in Washington, D.C., has announced grants totaling more than $13 million in support of melanoma research.
The awards, which include a total of $7.5 million from MRA's research funds and $5.6 million obtained through the organization's collaborative funding program, will support forty-two scientists at twenty-five academic institutions in four countries. The projects named to receive funding seek to advance the understanding of melanoma risk factors, identify new therapeutic approaches, and develop biomarkers that lead to the improvement of existing treatments.
MRA’s funding model includes a mechanism for collaborative funding through partnerships with companies, institutions, and foundations. In 2015, ten awards are being funded collaboratively, the most ever in a single year. In addition, MRA is funding a number of special opportunity awards, including the Bristol-Myers Squibb-MRA Established Investigator and Team Science Awards in Immunotherapy, the Society for Immunotherapy of Cancer-MRA Pilot Award, the SkinCeuticals-MRA Dermatology Young Investigator Award and the Amgen-MRA Established Investigator Academic Industry Partnership Award. Other partners include the Anna-Maria and Stephen Kellen Foundation, the Damon Runyon Cancer Research Foundation, the King Family, Leveraged Finance Fights Melanoma, Merck (known as MSD outside the U.S. and Canada), the Rising Tide Foundation for Clinical Cancer Research, the Society for Immunotherapy of Cancer, Sotheby’s, and the Tara Miller Foundation.
"These grants represent a diverse cross section of science focused on advancing our understanding of melanoma," said Debra Black, co-founder and chair of MRA. "We are delighted to have support from partners across industries, including academic institutions and private donors, who have joined together in order to maximize impact in combating this often devastating disease."
For more information on the 2015 grants, visit the MRA website.